Side Effects of rimegepant: A Synthesis of Findings from 9 Studies

  1. Home
  2. Side Effects of rimegepant
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of rimegepant: A Synthesis of Findings from 9 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of rimegepant: A Synthesis of Findings from 9 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key Research Findings

Rimegepant is a new drug developed for the acute treatment of migraine. It works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule that is involved in the development of migraine headaches. Clinical trials have shown that rimegepant is effective in treating migraine headaches. 4 . Furthermore, rimegepant has been shown to be generally safer than existing treatments, with a more tolerable side-effect profile. 4 .

Reasons for Side Effects

Rimegepant's side effects are likely caused by its action on the CGRP receptor. CGRP is a molecule involved in various bodily functions, including blood vessel dilation and inflammation. Rimegepant's ability to block CGRP may have some impact on these functions, leading to certain side effects.

Common Side Effects

Fatigue

One of the common side effects of rimegepant is fatigue. 2 . This may be due to the fact that CGRP is involved in blood vessel dilation, and rimegepant may cause fatigue by reducing blood vessel dilation.

Gastrointestinal Side Effects

Gastrointestinal side effects are also common with rimegepant. 2 . Constipation, diarrhea, abdominal pain, and nausea have been reported. 2 . These side effects could be linked to CGRP's role in regulating gastrointestinal motility. Rimegepant's action on CGRP may potentially disrupt this motility, leading to gastrointestinal issues.

Other Side Effects

Other side effects of rimegepant include dizziness, drowsiness, and rash. 2 . These side effects suggest that rimegepant may interact with other receptors besides CGRP. Further research is necessary to understand these interactions.

Measures to Address Side Effects

Fatigue

If you experience fatigue, getting enough rest can be helpful. Consuming caffeine may also offer some relief.

Gastrointestinal Side Effects

If you experience gastrointestinal side effects, consider making changes to your diet and lifestyle. You can also consult a pharmacist or doctor for appropriate treatment options.

Other Side Effects

If you experience any other side effects, it's important to seek advice from your pharmacist or doctor.

Comparison Between Studies

Commonalities of Studies

Numerous studies have demonstrated that rimegepant is an effective treatment for migraine. 9 4 . Additionally, these studies have shown that rimegepant has a more favorable side-effect profile compared to existing treatments such as triptans. 4 .

Differences Between Studies

There might be variations in the effectiveness and side effects of rimegepant depending on the specific study. These variations could be attributed to differences in study design and participant characteristics.

Precautions for Real-Life Applications

While rimegepant has proven to be effective in treating migraine, it's crucial to remember that, like any medication, it can have side effects. It is essential to consult with your doctor before starting rimegepant and to follow their instructions carefully regarding dosage and administration.

Limitations of Current Research

Long-term safety data on rimegepant is still limited. The impact of rimegepant on pregnancy and lactation also remains unclear. Therefore, consulting with a doctor is crucial when considering rimegepant, especially for pregnant or breastfeeding women.

Future Research Directions

Future research should focus on further evaluating the long-term safety of rimegepant. Investigating its impact on pregnancy and lactation is also essential. Additionally, understanding how rimegepant interacts with other medications is crucial for safe and effective use.

Conclusion

Rimegepant has emerged as a promising treatment for migraine, demonstrating effectiveness and safety in clinical trials. 9 4 . However, like any medication, it comes with the potential for side effects. Consulting with your doctor, discussing any concerns, and adhering to their instructions is crucial for safe and effective use of rimegepant.

Literature analysis of 9 papers
Positive Content
8
Neutral Content
1
Negative Content
0
Article Type
0
1
1
4
9
2.

Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.

Author: DongGuojun, KjærgaardNaoko Adachi, ShakibfarSaeed, SessaMaurizio

migraine treatment
ubrogerpant/rimegepant safety
ADRs

This study pooled estimates of the incidence of adverse drug reactions (ADRs) for ubrogepant and rimegepant and used meta-regression to identify correlations between ADRs and patient characteristics.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.

Author: RissardoJamir Pitton, CapraraAna Letícia Fornari

Migraine prevention
Hemodynamic impairment

The new generation of CGRP antagonists, including rimegepant, ubrogepant, atogepant, and zavegepant, are effective for the acute and/or preventive treatment of migraines. While generally well-tolerated, long-term safety concerns remain, and careful pharmacovigilance is crucial. Further research is needed to assess their long-term effects and compare them with triptans, especially in elderly populations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Rimegepant for the treatment of migraine.

Author: BergerAmnon A, WinnickAriel, CarrollAustin H, WelschmeyerAlexandra, LiNathan, ColonMarc, PaladiniAntonella, RamírezGiovanni F, HasoonJamal, CornettElyse M, SongJaehong, VarrassiGiustino, KayeAdam M, KayeAlan D, GantiLatha

Migraine treatment
Chronic migraine

Migraine is a common headache disorder. While traditional treatments for migraine often focus on acute pain relief and prevention, new drugs targeting CGRP, a key factor in migraine development, are showing promise. Rimegepant, a new CGRP antagonist, has been found to be effective in treating acute migraine attacks and may also be helpful in preventing them.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.

Author: BermanGary, CroopRobert, KudrowDavid, HalversonPhilip, LovegrenMeghan, ThiryAlexandra C, ConwayCharles M, CoricVladimir, LiptonRichard B

Migraine treatment
Nasopharyngitis

This study found that oral rimegepant, when used as an oral acute treatment in patients receiving calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) as preventive treatment, was well tolerated; no safety issues were identified.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

8.

Targeting CGRP and 5-HT<sub>1F</sub> Receptors for the Acute Therapy of Migraine: A Literature Review.

Author: Moreno-AjonaDavid, ChanCalvin, Villar-MartínezMaría Dolores, GoadsbyPeter J

New migraine treatments
Targeted acute therapy

Emerging acute migraine treatments include CGRP receptor antagonists, gepants, and 5-HT1F receptor agonists. Phase III clinical trials of lasmiditan, rimegepant and ubrogepant met their primary endpoints, suggesting that the options for migraine-targeted acute therapy will soon increase.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Gepants for the treatment of migraine.

Author: NegroAndrea, MartellettiPaolo

Cardiovascular contraindications
Headache recurrence
Incomplete pain relief

Calcitonin gene-related peptide (CGRP) receptor antagonists, a new class of drugs, show promise for the acute treatment of migraine. They are primarily developed to address the limitations of triptans, the current standard of care, which include incomplete pain relief, high rates of headache recurrence, and side effects. CGRP is a key target for migraine treatments currently under development.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.